| abstract |
The present invention relates to novel bicyclic thiazoles which inhibit Trat2- and Nck-interacting kinases (TNIKs) and can therefore be administered as TNIK inhibitors in cancer patients, especially in patients with solid cancers, such as colorectal cancer , pancreatic cancer, non-small cell lung cancer, prostate cancer, or breast cancer. The bicyclic thiazole compound is represented by the following formula (I) (wherein R 1 , R 2 , R 3 and Q are as defined in the description), or a pharmaceutically acceptable salt thereof. |